Cutting edge: Identification of a pre-ligand assembly domain (PLAD) and ligand binding site in the IL-17 receptor

Journal of Immunology

Volumn 179, Issue 10, 2007, Pages 6379-6383

  Kramer, Jill M ^a   Hanel, Walter ^a   Shen, Fang ^a   Isik, Nilgun ^d   Malone, James P ^a   Maitra, Amarnath ^a   Sigurdson, Wade ^a   Swart, David ^c   Tocker, Joel ^c   Jin, Tian ^d   Gaffen, Sarah L ^a,b,e  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c AMGEN INC   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; FIBRONECTIN 1; FIBRONECTIN 2; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; UNCLASSIFIED DRUG; IL17R PROTEIN, HUMAN; LIGAND;

ARTICLE; BINDING AFFINITY; BINDING SITE; COMPUTER MODEL; CONTROLLED STUDY; EMBRYO; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; CELL LINE; CHEMICAL STRUCTURE; GENETICS; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; PEPTIDE MAPPING; PROTEIN BINDING; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; TWO HYBRID SYSTEM;

BINDING SITES; CELL LINE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; INTERLEUKIN-17; LIGANDS; LYMPHOCYTES; MODELS, MOLECULAR; PEPTIDE MAPPING; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, INTERLEUKIN-17; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 38449092511     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.10.6379     Document Type: Article

References (33)

1. Weaver, C. T., R. D. Hatton, P. R. Mangan, and L. E. Harrington. 2007. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25: 821-852.
2. Cua, D. J., and R. A. Kastelein. 2006. TGF-β, a "double agent" in the immune pathology war. Nat. Immunol. 7: 557-559.
3. Chen, Y., C. L. Langrish, B. McKenzie, B. Joyce-Shaikh, J. S. Stumhofer, T. McClanahan, W. Blumenschein, T. Churakovsa, J. Low, L. Presta, et al. 2006. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 116: 1317-1326.
4. Lubberts, E., M. I. Koenders, and W. B. van den Berg. 2005. The role of T cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res. Ther. 7: 29-37.
5. Kikly, K., L. Liu, S. Na, and J. D. Sedgwick. 2006. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr. Opin. Immunol. 18: 670-675.
6. Weaver, C. T., L. E. Harrington, P. R. Mangan, M. Gavrieli, and K. M. Murphy. 2006. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24: 677-688.
7. Toy, D., D. Kugler, M. Wolfson, T. Vanden Bos, J. Gurgel, J. Derry, J. Tocker, and J. Peschon. 2006. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J. Immunol. 177: 36-39.
8. Kramer, J. M., L. Yi, F. Shen, A. Maitra, X. Jiao, T. Jin, and S. L. Gaffen. 2006. Cutting edge: evidence for ligand-independent multimerization of the IL-17 receptor. J. Immunol. 176: 711-715.
9. Chan, F. K., H. J. Chun, L. Zheng, R. M. Siegel, K. L. Bui, and M. J. Lenardo. 2000. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288: 2351-2354.
10. Constantinescu, S. N., T. Keren, M. Socolovsky, H. Nam, Y. I. Henis, and H. F. Lodish. 2001. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc. Natl. Acad. Sci. USA 98: 4379-4384.
11. Gadd, S. L., and C. V. Clevenger. 2006. Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol. Endocrinol. 20: 2734-2746.
12. Latz, E., A. Verma, A. Visintin, M. Gong, C. M. Sirois, D. C. Klein, B. G. Monks, C. J. McKnight, M. S. Lamphier, W. P. Duprex, T. Espevik, and D. T. Golenbock. 2007. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat. Immunol. 8: 772-779.
13. Chan, F. K. 2007. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 37: 101-107.
14. Siegel, R. M., J. K. Frederiksen, D. A. Zacharias, F. K. Chan, M. Johnson, D. Lynch, R. Y. Tsien, and M. J. Lenardo. 2000. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288: 2354-2357.
15. Sedger, L. M., S. R. Osvath, X. M. Xu, G. Li, F. K. Chan, J. W. Barrett, and G. McFadden. 2006. Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death. J. Virol. 80: 9300-9309.
16. Deng, G. M., L. Zheng, F. K. Chan, and M. Lenardo. 2005. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat. Med. 11: 1066-1072.
17. Jefferys, B. R., L. A. Kelley, M. J. Sergot, J. Fox, and M. J. Sternberg. 2006. Capturing expert knowledge with argumentation: a case study in bioinformatics. Bioinformatics 22: 924-933.
18. Shen, F., M. J. Ruddy, P. Plamondon, and S. L. Gaffen. 2005. Cytokines link osteoblasts and inflammation: microarray analysis of interleukin-17- and TNF-α-induced genes in bone cells. J. Leukocyte Biol. 77: 388-399.
19. Maitra, A., F. Shen, W. Hanel, K. Mossman, J. Tocker, D. Swart, and S. L. Gaffen. 2007. Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression. Proc. Natl. Acad. Sci. USA 104: 7506-7511.
20. Xu, X., M. Meier-Schellersheim, X. Jiao, L. E. Nelson, and T. Jin. 2005. Quantitative imaging of single live cells reveals spatiotemporal dynamics of multistep signaling events of chemoattractant gradient sensing in Dictyostelium. Mol. Biol. Cell 16: 676-688.
21. Yi, L., J. Fang, N. Isik, J. Chim, and T. Jin. 2006. HIV gp120-induced interaction between CD4 and CCR5 requires cholesterol-rich microenvironments revealed by live cell fluorescence resonance energy transfer imaging. J. Biol. Chem. 281: 35446-35453.
22. Novatchkova, M., A. Leibbrandt, J. Werzowa, A. Neubuser, and F. Eisenhaber. 2003. The STIR-domain superfamily in signal transduction, development and immunity. Trends Biochem. Sci. 28: 226-229.
23. Shen, F., Z. Hu, J. Goswami, and S. L. Gaffen. 2006. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J. Biol. Chem. 281: 24138-24148.
24. Feldmann, M., and L. Steinman. 2005. Design of effective immunotherapy for human autoimmunity. Nature 435: 612-619.
25. Bazan, J. F. 1990. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA 87: 6934-6938.
26. Ruoslahti, E. 1988. Fibronectin and its receptors. Annu. Rev. Biochem. 57: 375-413.
27. Wijdenes, J., P. C. Heinrich, G. Muller-Newen, C. Roche, Z. J. Gu, C. Clement, and B. Klein. 1995. Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Eur. J. Immunol. 25: 3474-3481.
28. Livnah, O., E. A. Stura, S. A. Middleton, D. L. Johnson, L. K. Jolliffe, and I. A. Wilson. 1999. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283: 987-990.
29. Haudenschild, D. R., S. B. Curtiss, T. A. Moseley, and A. H. Reddi. 2006. Generation of interleukin-17 receptor-like protein (IL-17RL) in prostate by alternative splicing of RNA. Prostate 66: 1268-1274.
30. Murphy, J. M., and I. G. Young. 2006. IL-3, IL-5, and GM-CSF signaling: crystal structure of the human β-common receptor. Vitam. Horm. 74: 1-30.
31. Gaffen, S. L. 2001. Signaling domains of the interleukin-2 receptor. Cytokine 14: 63-77.
32. Chan, F. K. 2000. The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function. Ann. Rheum. Dis. 59(Suppl. 1): i50-i53.
33. Tanner, M. J., W. Hanel, S. L. Gaffen, and X. Lin. 2007. CARMA1 Coiled-coil domain is involved in the oligomerization and subcellular localization of CARMA1, and is required for T cell receptor-induced NF-κB activation. J. Biol. Chem. 282: 17141-17147.